Antiobesity Medications: Expert Compares Benefits, Drawback Among Classes

Semaglutide 7.2 mg Achieves Weight Reduction of 21% in Late-Stage STEP UP Trial

News

Video

Obesity specialist Sandra Christensen, MSN, ARNP, compares the benefits and drawbacks among older antiobesity drugs and newer GLP-1RAs liraglutide and semaglutide 2.4 mg.

In a recent interview with Patient Care Online, medical weight management specialist Sandra Christensen, MSN, ARNP, was asked the following question:

What are the benefits and drawbacks to the different classes of antiobesity medications?

Ms Christensen discusses how the different classes of antiobesity medications compare in cost, side effect profiles, and more in the video below.

For a primer on common antiobesity medications, check out part 1 of our interview with Ms Christensen: Antiobesity Medications: Expert Discusses Older, Newer Therapies

Sandra Christensen, MSN, ARNP, is the owner of Integrative Medical Weight Management in Seattle, Washington.

Related Content

January 17th 2025

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

The 20.7% weight loss with the high-dose of semaglutide bested the mean reduction of 17.5% seen with semaglutide 2.4 mg, according to Novo Nordisk.

August 30th 2023

FDA Proposes Sustained 5% Weight Loss to Establish Efficacy of New Antiobesity Medications

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

January 8th 2025

Obesity & Type 2 Diabetes: An Expert Discussion

In an unusual step, the agency's draft guidance recommends the efficacy benchmark for drug approval while emphasizing clinical trial structure and cohort development.

June 30th 2023

CagriSema Leads to Weight Reduction of Approximately 23% in Phase 3 REDEFINE 1 Clinical Trial, Short of the 25% Expected

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

CagriSema Leads to Weight Reduction of Approximately 23% in Phase 3 REDEFINE 1 Clinical Trial / image credit ©JHVE photo/stock.adobe.com

December 20th 2024

Investigational Maridebart Cafraglutide Shows Promise for Obesity, T2D: Daily Dose

The 22.7% weight loss at 68 weeks places CagriSema essentially on par with, not superior to, competing antiobesity drugs including Lilly's tirzepatide.

December 17th 2024

Semaglutide 7.2 mg Achieves Weight Reduction of 21% in Late-Stage STEP UP Trial

Your daily dose of the clinical news you may have missed.

Related Content

January 17th 2025

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

The 20.7% weight loss with the high-dose of semaglutide bested the mean reduction of 17.5% seen with semaglutide 2.4 mg, according to Novo Nordisk.

August 30th 2023

FDA Proposes Sustained 5% Weight Loss to Establish Efficacy of New Antiobesity Medications

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

January 8th 2025

Obesity & Type 2 Diabetes: An Expert Discussion

In an unusual step, the agency's draft guidance recommends the efficacy benchmark for drug approval while emphasizing clinical trial structure and cohort development.

June 30th 2023

CagriSema Leads to Weight Reduction of Approximately 23% in Phase 3 REDEFINE 1 Clinical Trial, Short of the 25% Expected

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

December 20th 2024

Investigational Maridebart Cafraglutide Shows Promise for Obesity, T2D: Daily Dose

The 22.7% weight loss at 68 weeks places CagriSema essentially on par with, not superior to, competing antiobesity drugs including Lilly's tirzepatide.

December 17th 2024